Zepbound Mounjaro
-
Biotech & Health Weekly: The Week a New Drug Class Got Approved
Thirteen years of research. One FDA approval. Arvinas crossed the finish line on May 1 with the first PROTAC therapy ever cleared by a regulator. The same day, Eli Lilly reported the most dominant quarter in GLP-1 history. A week later, Novo Nordisk answered with its own numbers. The biotech M&A machine kept running in…
